Quick Answer
Whitehawk Therapeutics, Inc. reported R&D Expense of $90.96 million for fiscal year 2025.
Whitehawk Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $90.96M | +78.3% |
| 2024 | $51.03M | +4.3% |
| 2023 | $48.93M | +49.8% |
| 2022 | $32.66M | +66.0% |
| 2021 | $19.67M | +31.1% |
| 2020 | $15.01M | +17.0% |
| 2019 | $12.82M | -28.2% |
| 2018 | $17.85M | +47.0% |
| 2017 | $12.15M | +6.9% |
| 2016 | $11.37M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.35M | +43.5% | -70.6% |
| June 30, 2025 | $48.81M | +272.8% | +455.4% |
| March 31, 2025 | $8.79M | -35.3% | -12.1% |
| September 30, 2024 | $10.00M | -15.9% | -23.6% |
| June 30, 2024 | $13.09M | -1.7% | -3.7% |
| March 31, 2024 | $13.59M | +24.1% | +14.3% |
| September 30, 2023 | $11.89M | +35.5% | -10.7% |
| June 30, 2023 | $13.31M | +72.3% | +21.5% |
- Whitehawk Therapeutics, Inc. showed an increase of +78.3% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Whitehawk Therapeutics, Inc.’s r&d expense has grown by 700.2% (from $11.37 million to $90.96 million).
- The most recent figure is from Whitehawk Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: